Pemfexy FDA Approval History
Last updated by Judith Stewart, BPharm on March 1, 2020.
FDA Approved: Yes (First approved February 8, 2020)
Brand name: Pemfexy
Generic name: pemetrexed
Dosage form: Injection
Company: Eagle Pharmaceuticals, Inc.
Treatment for: Non-Small Cell Lung Cancer, Malignant Pleural Mesothelioma
Pemfexy (pemetrexed for injection) is a branded alternative to Alimta for the treatment of nonsquamous non-small cell lung cancer and malignant pleural mesothelioma.
Pemfexy is a folate analog metabolic inhibitor indicated:
- in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic non-squamous, non-small cell lung cancer (NSCLC).
- as a single agent for the maintenance treatment of patients with locally advanced or metastatic non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first line chemotherapy.
- as a single agent for the treatment of patients with recurrent, metastatic non-squamous NSCLC after prior chemotherapy.
Development timeline for Pemfexy
|Feb 10, 2020||Approval FDA Approves Pemfexy (pemetrexed for injection) as a Branded Alternative to Alimta|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.